BNP/PUT/ELI LILLY & CO/650/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 20:50:27 03/07/2024 BST | ||
| 0.87 EUR | +6.10% |
|
| Current month | +15.79% | ||
| 1 month | -41.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 0.88 | +7.32% |
| 02/07/24 | 0.82 | +12.33% |
| 01/07/24 | 0.73 | -3.95% |
| 28/06/24 | 0.76 | -2.56% |
| 27/06/24 | 0.78 | -4.88% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC84LE |
| ISIN | DE000PC84LE2 |
| Date issued | 30/04/2024 |
| Strike | 650 $ |
| Maturity | 17/01/2025 (198 Days) |
| Parity | 10 : 1 |
| Emission price | 3.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.51 € |
|---|---|
| Lowest since issue | 0.7 € |
| Spread | 0.11 € |
| Spread % | 11.22% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
